Abstract

BackgroundThe precise immune responses mediated by HLA class I molecules such as HLA-B*27:05 and HLA-B*57:01 that protect against HIV disease progression remain unclear. We studied a CRF01_AE clade HIV infected donor-recipient transmission pair in which the recipient expressed both HLA-B*27:05 and HLA-B*57:01.ResultsWithin 4.5 years of diagnosis, the recipient had progressed to meet criteria for antiretroviral therapy initiation. We employed ultra-deep sequencing of the full-length virus genome in both donor and recipient as an unbiased approach by which to identify specific viral mutations selected in association with progression. Using a heat map method to highlight differences in the viral sequences between donor and recipient, we demonstrated that the majority of the recipient’s mutations outside of Env were within epitopes restricted by HLA-B*27:05 and HLA-B*57:01, including the well-studied Gag epitopes. The donor, who also expressed HLA alleles associated with disease protection, HLA-A*32:01/B*13:02/B*14:01, showed selection of mutations in parallel with disease progression within epitopes restricted by these protective alleles.ConclusionsThese studies of full-length viral sequences in a transmission pair, both of whom expressed protective HLA alleles but nevertheless failed to control viremia, are consistent with previous reports pointing to the critical role of Gag-specific CD8+ T cell responses restricted by protective HLA molecules in maintaining immune control of HIV infection. The transmission of subtype CRF01_AE clade infection may have contributed to accelerated disease progression in this pair as a result of clade-specific sequence differences in immunodominant epitopes.Electronic supplementary materialThe online version of this article (doi:10.1186/s12977-015-0179-z) contains supplementary material, which is available to authorized users.

Highlights

  • The precise immune responses mediated by Human leukocyte antigen (HLA) class I molecules such as HLA-B*27:05 and HLAB*57:01 that protect against human immunodeficiency virus (HIV) disease progression remain unclear

  • B*13:02/14:01 C*06:02/08:02) is believed to have acquired HIV infection in Thailand, and subsequently to have infected the female recipient (HLA-A*02:01/02:01 B*27:05/57:01 C*01:02/06:02) in the UK. Both partners were diagnosed more than 2 years later when the recipient was HIV-tested during pregnancy

  • As evidence to support the direction of transmission suggested by the clinical history, we found that an HLA-B*14:01 associated escape mutation, group-specific antigen (Gag)-K302R present in the HLA-B*14:01-positive donor’s autologous virus, was transmitted to the HLAB*14:01-negative recipient and subsequently reverted to wild-type in the recipient (Figure 2)

Read more

Summary

Introduction

The precise immune responses mediated by HLA class I molecules such as HLA-B*27:05 and HLAB*57:01 that protect against HIV disease progression remain unclear. Most studies of immune control in HIV-infected subjects expressing protective HLA alleles such as HLA-B*57:01 and B*27:05 have focused on Gag, and in particular the Brener et al Retrovirology (2015) 12:55 dominant CD8+ T cell responses targeting epitopes within p24 Gag. We investigated the case of an HIV infected transmission pair in which the recipient expressed both HLA-B*27:05 and HLA-57:01. We investigated the case of an HIV infected transmission pair in which the recipient expressed both HLA-B*27:05 and HLA-57:01 Despite expression of these protective HLA alleles, disease progression occurred over four years from aviremia (viral load

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.